HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics

American Journal of Kidney Diseases · Elsevier

Аннотация

Publication date: January 2027 Source: American Heart Journal, Volume 303 Author(s): Marion M. Mafham, Mohammed G. Zayed, Rory Collins, Marc S. Sabatine, Jane Armitage, Dominic Brittain, Bruno R. da Costa, Fang Chen, Michelle A. Goonasekera, Michael Hill, Jemma C. Hopewell, Martin J. Landray, Michael D. Lay, Anastasia Lesogor, Aldo P. Maggioni, David A. Morrow, Michelle Nunn, Michelle L. O’Donoghue, Kausik K. Ray, Adel Rizkala

Читать у издателя →

Похожие статьи